CTLA4 and cancer: Based on the scRNA-seq results, among the reported relevant immune checkpoint proteins, Prmt9 KD significantly upregulated PD-L1 in cancer cells (Fig. 8a,b), although PD-L2 and CTLA-4 were also modestly upregulated (Fig. 8a,b and Extended Data Fig. 9a,b).